Company - Highlight Therapeutics

Transforming
Dermato-oncology
for Better Health

Our Company

We are a private, clinical-stage biotechnology company dedicated to unlocking the full potential of dermatO-oncology.

Scientific Advisory Board World-renowned experts dedicated to advancing the field of intra-lesional treatments. Their collective knowledge and strategic insights drive our commitment to revolutionize the treatment landscape for skin cancer patients worldwide.

Experienced Leadership
Team & Board

Carlos Paya MD, PhD

Executive Chairman of the Board

Damia Tormo

Board Member

Janwillem Naesens

Regulatory Strategy/SAB

Shahzad Malik

Board Member

Marisol Quintero, PhD, MBA

CEO/Board Member

Zuzana Jirakova, MD, PhD

Chief Medical Officer

Scientific Advisory Board with
Thought Leaders in the Field

Antoni Ribas MD, PhD

Professor of Medicine, Surgery and Molecular & Medical Pharmacology at UCLA

Georgina Long AO, BSc, PhD, MBBS, FRACP

Co-Medical Director of Melanoma Institute of Australia (MIA)

Ralph R. Weichselbaum MD

Ludwig Professor of Radiation and Cellular Oncology, University of Chicago

Ignacio Melero MD, PhD

Head of Immunology, Universidad de Navarra

Our partners Together, we're advancing
groundbreaking skin cancer treatments.

It received a grant of more than €600,000 in 2016 from Spain’s Centre for the Development of Industrial Technology (CDTI) to support pre-clinical and clinical research into BO-112.

In 2019 we have received a public grant to support NOELIA´s project (RETOS nº RTC2019-006860-1: Ensayo clínico fase I/II: nuevo enfoque terapéutico para el tratamiento de tumores sólidos con metástasis hepática) from the Spanish Ministerio de Ciencia e Innovación

Unlocking the potential of
dermato-oncology treatment

Contact us